Patents
Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210)
07/2005
07/28/2005WO2005068628A2 Methods for nucleic acid isolation and kits using solid phase material
07/28/2005WO2005068627A1 Methods for nucleic acid isolation and kits using a microfluidic device and concentration step
07/28/2005WO2005068626A1 Methods for nucleic acid isolation and kits using a microfluidic device and sedimenting reagent
07/28/2005WO2005068625A1 Plants transformed for elevated levels of gallic acid and methods of producing said plants
07/28/2005WO2005068624A1 Method of screening remedy for rheumatoid arthritis
07/28/2005WO2005068623A1 Method of screening remedy for rheumatoid arthritis
07/28/2005WO2005068621A1 Apatite particle, method of preparing the same, gene composite and method of gene introduction
07/28/2005WO2005068617A2 Fungal beta-glucuronidase genes and gene products
07/28/2005WO2005068616A2 Immunokinases
07/28/2005WO2005068611A1 Method for obtaining a singular cell model capable of reproducing in vitro the metabolic idiosyncrasy of humans
07/28/2005WO2005068610A1 Novel culture systems for ex vivo development
07/28/2005WO2005068505A1 Fusion protein comprising tatdmt polypeptide
07/28/2005WO2005068504A1 Inflammatory cytokine inhibitor
07/28/2005WO2005068500A1 Process for the purification of bacterially expressed proteins
07/28/2005WO2005068499A1 Compositions and methods for the high efficiency expression of the transforming growth factor-beta supergene family
07/28/2005WO2005068498A2 Human therapeutic cells secreting nerve growth factor
07/28/2005WO2005068495A1 Silk thread containing spider thread protein and silkworm producing the silk thread
07/28/2005WO2005067981A1 Gene therapy for tumor using minus-strand rna virus vector encoding immunostimulating cytokine
07/28/2005WO2005067971A1 Drug for preventing and treating arteriosclerosis
07/28/2005WO2005067709A2 Chimeric murine model comprising human hepatocytes user for screening compounds
07/28/2005WO2005067699A1 Methods of expressing heterologous protein in plant seeds using monocot non seed-storage protein promoters
07/28/2005WO2005067692A2 Detection and quantification of analytes in solution using polymers
07/28/2005WO2005067665A2 Activatable ribozymal purification constructs and methods of use
07/28/2005WO2005067632A2 Lipid compositions and use thereof
07/28/2005WO2005067601A2 Vectors for recombinant protein expression in e.coli
07/28/2005WO2005067583A2 Immunoliposome-nucleic acid amplication (ilnaa) assay
07/28/2005WO2005067512A2 Novel carotenoid hydroxylases for use in engineering carotenoid metabolism in plants
07/28/2005WO2005067506A2 Method for monitoring and generating high capacity gutless adenoviral vector
07/28/2005WO2005067491A2 Toxin complex proteins and genes from xenorhabdus bovienii
07/28/2005WO2005067478A2 Recombinant icosahedral virus like particle production in pseudomonads
07/28/2005WO2005067368A2 Production of glucagon like peptide 2 and analogs
07/28/2005WO2005061709A3 Variable valve apparatus and methods
07/28/2005WO2005054438A3 Nucleic acid molecules containing recombination sites and methods of using the same
07/28/2005WO2005052171A3 Retroviral and lentiviral vectors
07/28/2005WO2005052167A3 Plasmid maintenance
07/28/2005WO2005051983A3 Oligomeric complexe formation of recombinant multi subunit chimeric polypeptides
07/28/2005WO2005051970A3 Highly parallel dna synthesiser based on matrices
07/28/2005WO2005051433B1 Method for treating human tumor cells with a newcastle disease virus strain and a chemotherapeutic agent
07/28/2005WO2005041944A3 Methods and compositions for promoting axon regeneration and cell replacement therapy
07/28/2005WO2005041880A3 RhPV AS A MODEL FOR HPV-INDUCED CANCERS
07/28/2005WO2005040382A3 Cherkasky fusion proteins containing antibody-, antigen- and microtubule-binding regions and immune response-triggering regions
07/28/2005WO2005040212A3 Orthogonal gene switches
07/28/2005WO2005033309A3 Plant promoters and methods of use thereof
07/28/2005WO2005030931A3 Altering a b cell pathology using self-derived antigens in conjunction with specific-binding cytoreductive agent
07/28/2005WO2005027710A3 Methods for identifying subjects at risk of melanoma and treatments thereof
07/28/2005WO2005026337A3 Adenoviral vector for infecting cells deficient in a car receptor
07/28/2005WO2005026322A3 siRNA ENCODING CONSTRUCTS AND METHODS FOR USING THE SAME
07/28/2005WO2005019428A3 Regulation of polynucleic acid activity and expression
07/28/2005WO2005019252A8 Novel fluorescent and colored proteins, and polynucleotides that encode these proteins
07/28/2005WO2005017102A3 Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins
07/28/2005WO2005013682A3 Animal model for the analysis of tumor metastasis
07/28/2005WO2005009366A3 Restoring vascular function
07/28/2005WO2005003289A3 Ap1 amine oxidase variants
07/28/2005WO2004110362A3 Immunotherapeutics for biodefense
07/28/2005WO2004089189A3 Minimally-invasive imaging of viral gene therapy and presurgical applications thereof
07/28/2005WO2004070032A8 Method of preparing template dna to be used in polymerase chain reaction from microbial cells
07/28/2005WO2004069870B1 Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions
07/28/2005WO2004056848A3 Elevation of oil levels in brassica plants
07/28/2005WO2004039946A3 Methods for increasing total oil levels in plants
07/28/2005WO2004037977A3 Use of chimeric nucleases to stimulate gene targeting
07/28/2005WO2004035806A3 Methods and nucleic acids for the analysis of cpg dinucleotide methylation status associated with the calcitonin gene
07/28/2005WO2004033620A3 Methods and compositions for therapeutic use of rna interference
07/28/2005WO2004003820A3 System, method, device, and computer program product for extraction, gathering, manipulation, and analysis of peak data from an automated sequencer
07/28/2005WO2003103597A3 Methods of diagnosing & treating diabetes and insulin resistance
07/28/2005WO2003094088A8 Mouse olfactory receptor gene superfamily specification
07/28/2005WO2003093295A3 Secretion signal vectors
07/28/2005WO2003072035A8 Compositions and methods for the treatment of immune related diseases
07/28/2005WO2003027249A3 High-protein-phenotype-associated plant genes
07/28/2005WO2002072756A3 Feline immunodeficiency virus central dna flap
07/28/2005WO2002072028A3 Compositions and methods for modifying the content of polyunsaturated fatty acids in mammalian cells
07/28/2005WO2002055010A3 Pharmaceutical compositions comprising modified cns-derived peptides for promoting nerve regeneration and prevention of nerve degeneration
07/28/2005US20050166290 Expression cassettes and methods for delivery of animal vaccines
07/28/2005US20050166289 Small interfering RNA (siRNA)-mediated heritable gene manipulation in plants
07/28/2005US20050166288 Methods and vectors for site-specific recombination in plant cell plastids
07/28/2005US20050166287 Mag1 nucleic acid molecules and their uses
07/28/2005US20050166286 Use of naturally occurring antimicrobial polypeptides isolated from insects induced with plant pathogens; genetic engineering; fungicide
07/28/2005US20050166285 Endoglucanase gene promoter upregulated by nematodes
07/28/2005US20050166284 Plant activation of insect toxin
07/28/2005US20050166283 Methods for simultaneous control of lignin content and composition, and cellulose content in plants
07/28/2005US20050166282 Method and polynucleotides for determining translational efficiency of a codon
07/28/2005US20050166281 Soybean cultivar 0509236
07/28/2005US20050166276 Light-repressible promoters
07/28/2005US20050166275 Transgenic animal model for chronic pancreatitis
07/28/2005US20050166274 Compositions and methods for the diagnosis and treatment of tumor
07/28/2005US20050166273 Rat model of diabetic nephropathy
07/28/2005US20050166272 Double stranded RNA sequences for use as models in defining and determining sequence complement necessary for RNA interfering activity; wreck and check mutational analysis; blocking agents
07/28/2005US20050166271 Transgenic plants; homologous screening of genome
07/28/2005US20050165245 Transferring drugs; antitumor agents, anticancer agents
07/28/2005US20050165226 Preparing oligonucleotides having phosphorothioate internucleoside linkage; using phenylacetyl disulfide reagent in a simplified solvent system to produce modified oligonucleotides; antiviral agents; antisense agents
07/28/2005US20050165225 Novel cytokine isolated from an insect
07/28/2005US20050165224 Inhibition of penicillin resistance in s. pneumoniae
07/28/2005US20050165219 Related to the thymic stromal cotransporter subfamily; can be used as models for the development of and aid in the identification of therapeutic proteins that modulate transporter activity
07/28/2005US20050164974 Ligand is covalently linked to polyoxyethylene glycol having specific binding affinity for vascular endothelial growth factor; SELEX method; improved pharmacokinetics
07/28/2005US20050164972 Cationic lipids capable of facilitating transport of biologically active agents or substances into cells; lipid aggregate macromolecular complex interacts with cells making the polyanionic macromolecule available for absorption and uptake by the cell
07/28/2005US20050164971 Acyclic and macrocyclic, aliphatic diammonium surfactants for use in forming lipid aggregates for drug delivery of macromolecules; improved versatility among different cell types and broadened range of molecules to be carried
07/28/2005US20050164970 Method for treating prostate cancer using siRNA duplex for androgen receptor
07/28/2005US20050164968 RNA interference mediated inhibition of ADAM33 gene expression using short interfering nucleic acid (siNA)
07/28/2005US20050164967 RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
07/28/2005US20050164966 Aging, cancer, autoimmune diseases, inflammatory/allergic diseases
07/28/2005US20050164965 DNA or RNA having a modified backbone or base and a section that hybridizes to an EphrinB2 or EphB4 transcript causing gene expression inhibition; antineoplastic and antiproliferative agents can be synergistically administered with a second agent